KR20230048523A - 헤테로아릴 및 헤테로사이클릴 화합물 - Google Patents

헤테로아릴 및 헤테로사이클릴 화합물 Download PDF

Info

Publication number
KR20230048523A
KR20230048523A KR1020237007667A KR20237007667A KR20230048523A KR 20230048523 A KR20230048523 A KR 20230048523A KR 1020237007667 A KR1020237007667 A KR 1020237007667A KR 20237007667 A KR20237007667 A KR 20237007667A KR 20230048523 A KR20230048523 A KR 20230048523A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
heteroalkyl
formula
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237007667A
Other languages
English (en)
Korean (ko)
Inventor
리차드 하이데브레흐트
크리스토퍼 피. 헹켄
오마르 데 파올리스
웨이헹 왕
매튜 뷰캐넌
Original Assignee
시질론 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시질론 테라퓨틱스, 인크. filed Critical 시질론 테라퓨틱스, 인크.
Publication of KR20230048523A publication Critical patent/KR20230048523A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020237007667A 2020-08-04 2021-08-04 헤테로아릴 및 헤테로사이클릴 화합물 Pending KR20230048523A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063060968P 2020-08-04 2020-08-04
US63/060,968 2020-08-04
PCT/US2021/044564 WO2022031862A2 (en) 2020-08-04 2021-08-04 Heteroaryl and heterocyclyl compounds

Publications (1)

Publication Number Publication Date
KR20230048523A true KR20230048523A (ko) 2023-04-11

Family

ID=80120142

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237007667A Pending KR20230048523A (ko) 2020-08-04 2021-08-04 헤테로아릴 및 헤테로사이클릴 화합물

Country Status (9)

Country Link
US (1) US20230303502A1 (cg-RX-API-DMAC10.html)
EP (1) EP4192468A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023536633A (cg-RX-API-DMAC10.html)
KR (1) KR20230048523A (cg-RX-API-DMAC10.html)
CN (1) CN116322777A (cg-RX-API-DMAC10.html)
AU (1) AU2021321433A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023002132A2 (cg-RX-API-DMAC10.html)
CA (1) CA3190778A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022031862A2 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4531879A1 (en) 2022-05-25 2025-04-09 Flagship Pioneering Innovations VI, LLC Compositions of secretory and/or catalytic cells and methods using the same
JP2025520113A (ja) 2022-06-03 2025-07-01 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー 組成物及び方法
IL328729A (en) 2023-12-01 2026-07-01 Sigilon Therapeutics Inc Methods for producing stem cell-derived islet-like cells, as well as populations and compositions comprising them

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2411197A (en) * 1996-04-30 1997-11-19 Affymax Technologies N.V. Methods for the synthesis of fmoc protected amines
CN103819403B (zh) * 2008-12-31 2017-01-04 阿德利克斯公司 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法
ES3036749T3 (en) * 2014-08-01 2025-09-23 Massachusetts Inst Technology Modified alginates for anti-fibrotic materials and applications
EP3215519A1 (en) * 2014-11-06 2017-09-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
US20180185368A1 (en) * 2014-11-06 2018-07-05 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
CR20180229A (es) * 2015-10-29 2018-08-24 Novartis Ag Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
KR20230156818A (ko) * 2016-10-03 2023-11-14 시질론 테라퓨틱스, 인크. 화합물, 장치, 및 이의 용도
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CN112203646A (zh) * 2018-04-04 2021-01-08 西吉隆医疗股份有限公司 可植入颗粒和相关方法

Also Published As

Publication number Publication date
JP2023536633A (ja) 2023-08-28
WO2022031862A2 (en) 2022-02-10
BR112023002132A2 (pt) 2023-04-11
US20230303502A1 (en) 2023-09-28
EP4192468A4 (en) 2024-09-11
WO2022031862A3 (en) 2022-03-24
CA3190778A1 (en) 2022-02-10
EP4192468A2 (en) 2023-06-14
AU2021321433A1 (en) 2023-03-02
CN116322777A (zh) 2023-06-23

Similar Documents

Publication Publication Date Title
RU2771311C2 (ru) Ингибитор fgfr и его медицинское применение
ES2559513T3 (es) Derivados de amina cíclica como antagonistas del receptor EP4
JP2023536633A (ja) ヘテロアリール及びヘテロシクリル化合物
AU2020350529B2 (en) Cyano-substituted cyclic hydrazine derivative and application thereof
AU2010289802C1 (en) Synthesis of a neurostimulative piperazine
CN105814013A (zh) 双环烷基化合物及合成
AU2013253539A1 (en) Benzamide derivative
JP2010535217A (ja) E1活性化酵素阻害剤の合成のためのプロセス
CA2788762C (en) Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it
KR20250028345A (ko) 진핵생물 개시 인자 2b의 조절제를 제조하는 공정
JP2026516129A (ja) Wee1-Yes二重標的阻害剤としてのピリミドマクロ複素環式化合物及びその応用
WO2020198583A1 (en) Bicyclic jak inhibitors and uses thereof
JP6940480B2 (ja) Fgfr阻害剤の合成方法
JP2025525622A (ja) Il-17モジュレーターとしてのイミダゾトリアジン誘導体
KR20240148351A (ko) 브루톤 티로신 키나제 억제제의 합성
US4517122A (en) Cyclic peptides
ES2977277T3 (es) Procesos para preparar (3R,4R)-1-bencil-n,4-dimetilpiperidin-3-amina o una de sus sales y procesos para preparar tofacitinib mediante el uso de la misma
AU2022240650B2 (en) Estrogen receptor antagonist
JP7432282B2 (ja) 高屈折率を示す、トリアジン環を有する新規なジヒドロオキサフォスファフェナントレン誘導体及びその製造方法
US4163014A (en) 3,4,5,6-Tetrahydropyromellitdiimides
WO2017213210A1 (ja) 複素環化合物
WO2025149985A1 (en) Methods of preparing melanocortin 4 receptor agonists
WO2012028331A1 (en) Substituted tetrahydropyrrolopyrazine derivatives
WO2013140331A1 (en) New 1, 2, 4-oxadiazol derivatives, process for their preparation and use thereof as intermediates in the preparation of indolic alkaloids
OA20759A (en) Benzimidazole derivatives.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000